Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — Investor Day (March 2024)
12 slides from Novo Nordisk A/s Class B's investor day presentation, Mar 7, 2024
Slide 1: Data science & AI
1 Data science & AI Novo Nordisk® Break-out session Data science & AI Thomas Senderovitz SVP Data Science Lars Fogh Iversen SVP R&ED Digital Science & Innovation 7 MARCH
Slide 2: Forward-looking statements
2 Data science & AI Break-out session Novo Nordisk® Forward-looking statements Novo Nordisk’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the statutory Annual Report 2023 and Form 20-F, which both were filed with the SEC in January 2024 in continuati
Slide 3: Novo Nordisk has a foundation to leverage data and AI
3 Data science & AI Break-out session Novo Nordisk® Novo Nordisk has a foundation to leverage data and AI Internal and external setup Artificial Intelligence is not new to Novo Nordisk Best-in-class clinical data Investments in best- within cardiometabolic space in-class HPC/GPU MIT/NN Post Doc on 1
Slide 4: AI brings innovation across the Novo Nordisk value chain
4 Data science & AI Break-out session Novo Nordisk® AI brings innovation across the Novo Nordisk value chain Research & early Clinical Product supply Commercial development development Identifying sub Target discovery AI-driven production Resource allocation and populations from RCTs optimisation fo
Slide 5: Novo Nordisk utilises best-in-class clinical data within the cardiometabolic space
5 Data science & AI Break-out session Novo Nordisk® Novo Nordisk utilises best-in-class clinical data within the cardiometabolic space Deploying data to enable AI Harmonising data from ~1,600 clinical trials Capabilities SELECT and STEP results providing best-in-class cardiometabolic data for new di
Slide 6: FounData makes billions of clinical data points accessible across the entire value chain
6 Data science & AI Break-out session Novo Nordisk® FounData makes billions of clinical data points accessible across the entire value chain Unleashing the power of data for secondary use Democratise data across the Novo Nordisk value chain A seamless infrastructure Researchers FounData where all da
Slide 7: NovoScribe platform enables automated authoring of structured documents
7 Data science & AI Break-out session Novo Nordisk® NovoScribe platform enables automated authoring of structured documents, reducing time to regulatory submissions Automated authoring Value generated today Potential to expand NovoScribe to full submission package automation • Automation of all docu
Slide 8: Pioneering methodology in collaboration with Microsoft out-performs best clinical standards in patient risk prediction
8 Data science & AI Break-out session Novo Nordisk® Pioneering methodology in collaboration with Microsoft out- performs best clinical standards in patient risk prediction Goals Input Model Results realised to date Predict Atherosclerosis risk ~8% increased accuracy in Identify Automated assigning C
Slide 9: Combining AI with high-throughput experimentation yields first-ever new compound class for amylin selection
9 Data science & AI Break-out session Novo Nordisk® Combining AI with high-throughput experimentation yields first-ever new compound class for amylin selection Inputs and process Realised value 1 billion First ever calcitonin-based amylin selective compound virtual molecules assessed identified in s
Slide 10: Bi-specific mini protein identified with animal-free evaluation
10 Data science & AI Break-out session Novo Nordisk® Bi-specific mini protein identified with animal-free evaluation and sets new standard for target discovery Goal Process Results Create a potent and selective Data from high-throughput Bi-specific mini protein identified molecule with extended half
Slide 11: Partnerships and collaborations play an important part in accelerating AI capabilities
11 Data science & AI Break-out session Novo Nordisk® Partnerships and collaborations play an important part in accelerating AI capabilities Valo Health partnership to develop and Other partnerships and collaborations Next steps discover novel treatments using AI Near-term Exploring investments in la
Slide 12: Closing remarks
12 Data science & AI Break-out session Novo Nordisk® Closing remarks Novo Nordisk leverages data and AI across the value chain Access to clinical data drives AI based innovation in Research & Development External partnerships and collaborations to continue playing an important role in reaching AI am